EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
独家：Roundhill Investments推出减肥ETF，用于投资Ozempic等重磅药物
Roundhill Investments launched a new exchange-traded fund (ETF) Tuesday.
朗德希尔投资周二推出了新的交易所交易基金（ETF）。
What Happened: The Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) marks a significant milestone as the world's first GLP-1 ETF.
发生了什么：朗德希尔 GLP-1 和减肥ETF（纳斯达克股票代码：OZEM）作为世界上第一个 GLP-1 ETF，标志着一个重要的里程碑。
Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most revolutionary advancements in the global pharmaceuticals industry.
朗德希尔断言，减肥药物，特别是 GLP-1 激动剂，是全球制药行业最具革命性的进步之一。
Notably, OZEM is the only ETF providing dedicated exposure to transformative weight loss stocks such as Eli Lilly & Co. (NYSE:LLY), the producer of Zepbound, and Novo Nordisk A/S (NYSE:NVO), the maker of Ozempic.
值得注意的是，OZEM是唯一一家专门投资礼来公司等变革性减肥股票的ETF。Zepbound的制片人纽约证券交易所代码：LLY）和Ozempic的制造商诺和诺德A/S（纽约证券交易所代码：NVO）。
"These new treatments work incredibly well," Roundhill CEO Dave Mazza told...
朗德希尔首席执行官戴夫...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。